ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Companies

Shanghai-listed WuXi AppTec to raise up to $1bn in Hong Kong IPO - Sources

HONG KONG (Nikkei Markets) -- Shanghai-listed drug research and development services company WuXi AppTec plans to raise up to HK$8.33 billion ($1.06 billion) from a listing in Hong Kong, two sources familiar with the matter said on Wednesday.

The company, also a group associate of Hong Kong-listed WuXi Biologics, is offering about 116.5 million shares in the initial public offering in a price range of HK$64.10 to HK$71.50 each, said the persons, who did not wish to be identified. The offering has an over-allotment option for up to 17.5 million shares, or 15% of the shares being offered.

The company, which listed its shares in Shanghai in May, earned 1.30 billion yuan ($187.6 million) in net profit for the six months ended Jun.e 30, up from 781.7 million yuan in the same period a year earlier. Its revenue during the period climbed to 4.41 billion yuan from 3.67 billion yuan, according to a draft prospectus filed with the stock exchange.

The Shanghai-listed shares were little changed at 78.33 yuan in early trading on Wednesday, while WuXi Biologics' shares gained 0.8% to HK$60.40.

WuXi AppTec's shares are expected to list in Hong Kong on Dec. 13.

Morgan Stanley Asia, Huatai Financial Holdings and Goldman Sachs (Asia) are the joint sponsors for the offering.

-- Amy Lam and Carrie Chen

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends May 26th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media